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Non-invasive monitoring of tumor therapy response helps in developing personalized treatment strategies. 
Here, we performed sequential positron emission tomography (PET) and diffusion-weighted magnetic 
resonance imaging (DW-MRI) to evaluate changes induced by a FOLFOX-like combination chemotherapy 
in colorectal cancer (CRC) xenografts, to identify the cellular and molecular determinants of these imaging 
biomarkers. 
Methods: Tumor bearing CD1 nude mice, engrafted with FOLFOX-sensitive Colo205 CRC xenografts, 
were treated with FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) in weekly intervals. On d1, d2, d6, d9 
and d13 of therapy, tumors were assessed by in vivo imaging and ex vivo analyses. In addition, HCT116 
xenografts, which did not respond to the FOLFOX treatment, were imaged on d1 of therapy.  
Results: In Colo205 xenografts, FOLFOX induced a profound increase in uptake of the proliferation PET 
tracer 3’-deoxy-3’-[18F]fluorothymidine ([18F]FLT), which was accompanied by increases in markers for 
proliferation (Ki67, TK1) and for activated DNA damage response (DDR; γH2AX), whereas the effect on 
cell death was minimal. As tracer uptake was unaltered in the HCT116 model, these changes appear to be 
specific for tumor response. 
Conclusion: We demonstrate that [18F]FLT PET can non-invasively monitor molecular alterations induced 
by a cancer treatment, including thymidine metabolism and DDR. The cellular or imaging changes may not, 
however, be directly related to therapy response as assessed by volumetric measurements.  





Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause for cancer 
related deaths worldwide (1). FOLFOX, the combination of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin 
(folinic acid), is a frequently employed therapy for CRC. The active metabolites of 5-FU disrupt RNA 
synthesis and inhibit thymidylate synthase (TS), an enzyme important for DNA synthesis. This TS inhibitory 
activity can be enhanced by leucovorin (2). The combination of these two agents has been shown to be 
superior to therapy with 5-FU alone in patients with advanced CRC (3). Oxaliplatin is a third generation 
platinum analogue, inducing DNA intra- and inter-strand crosslinks, which ultimately results in cell death 
(4). The addition of oxaliplatin to the combination of 5-FU and leucovorin is beneficial for outcome for 
instance in the adjuvant (5) setting. 
Molecular imaging can aid in early and non-invasive identification of patients not responding to therapy, 
allowing an early change of the treatment approach. This not only results in the reduction of unnecessary 
side effects for the patient, but also allows for early definition of effective treatment. Positron emission 
tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]FDG) is routinely used in the clinic for tumor 
therapy follow-up. A drawback of [18F]FDG is its accumulation in inflammatory lesions (6). The proliferation 
tracer 3’-deoxy-3’-[18F]fluorothymidine ([18F]FLT), a thymidine analogue, performs better than [18F]FDG with 
regards to selectivity. It has already been successfully employed for monitoring tumor response to therapy 
in a range of preclinical and clinical studies (7,8). [18F]FLT is phosphorylated by thymidine kinase 1 (TK1) 
and retained within proliferative cells. Therefore, its uptake reflects the thymidine salvage pathway (9), an 
alternative thymidine-to-DNA pathway to the de novo pathway, with the key enzyme TS. Thymidine 
phosphorylase (TP) affects [18F]FLT uptake by degrading thymidine, whereas [18F]FLT is resistant to the 
activity of this enzyme (10). It is well recognized that thymidine competes with [18F]FLT for cellular retention 
(11) and that this competition can be modified by TP (12,13). Moreover, TP activity plays a role in tumor 
angiogenesis, induces metastasis, and protects cancer cells against apoptosis (14). 
Another method for non-invasive monitoring of response to therapy is diffusion-weighted MRI (DW-MRI). 
Tumor cell killing as a consequence of successful therapy results in increased intercellular space and hence 




Here, we employed CRC models treated with a FOLFOX-like combination therapy, which we refer to as 
FOLFOX. We evaluate changes in uptake of the radiotracers [18F]FLT and [18F]FDG, as well as in ADC 
measured by DW-MRI, and analyze associated alterations within the tumors on a cellular level. This will 
allow a better understanding of tumor biology and factors affecting imaging biomarkers, paving the way for 
improved cancer therapy in the clinical setting. 
 
MATERIALS AND METHODS 
Animal model  
Colo205 and HCT116 cells were cultivated in DMEM or RPMI, respectively, supplemented with 10 % fetal 
calf serum and 100 U/mL penicillin and 100 µg/mL streptomycin. Animal procedures were performed in 
accordance with the German Laws for Animal Protection and were approved by the animal care committee 
of the local government (North Rhine-Westphalia State Agency for Nature, Environment and Consumer 
Protection). 5 x 106 Colo205 or 2 x 106 HCT116 cells were injected subcutaneously into the shoulder region 
of 6 to 8 week old female CD1 nude mice (Charles River Laboratories). Two tumors were inoculated per 
animal and growth was followed by digital caliper measurements (volume = ½ (length * width2)).  
Animals were assigned randomly into groups. FOLFOX therapy was applied at weekly intervals. The 
treatment was started with oxaliplatin (8 mg/kg, intraperitoneal) followed by leucovorin 1.5 h later 
(90 mg/kg, retrobulbar) and two doses of 5-FU (30 mg/kg at 2 h and 6 h after treatment initiation, 
intraperitoneal). All agents were obtained from the pharmacy of the University Hospital of Münster. Control 
animals were injected with the respective solvents at the same time points. 5-FU therapy consisted of two 
doses of 5-FU only (30 mg/kg each, given 4 h apart). The experimental schedule is presented in 
Supplemental Table 1.  
 
[18F]FLT PET imaging and analysis 
[18F]FLT was synthesized as reported previously (16). 10 MBq of tracer was injected into isoflurane 
anaesthetized mice. Imaging was performed 70 min - 90 min after tracer application using a quadHIDAC 
PET (Oxford Positron Systems, UK). A multimodal bed was used that was transferred to a Bruker MR 
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tomograph during the tracer acquisition period (for DW-MR imaging, see below), or to a CT scanner (Inveon, 
Siemens Medical Solutions, USA) after completion of the PET scan.   
Volumes of interest (VOIs) were drawn manually on anatomical images and transferred to the respective 
PET images using the in-house developed software for multimodal data analysis - MEDgical. The whole 
tumor was defined by the VOI and tracer uptake was expressed as SUVmax. Also other modes of 
quantification were performed, as shown in the Supplemental Material. These data confirm that the results 
and conclusions are not dependent on the method of analysis. 
 
DW-MR imaging 
A Bruker Biospec 9.4 T tomograph was employed to obtain data on water diffusion. First, T2-weighted 
images were acquired (2D rapid acquisition with relaxation enhancement (RARE), TR/TE 3600/40 ms, Rare 
factor 8, FOV 35 mm, 256 matrix, slice thickness 1 mm, 4 slices per tumor at biggest tumor diameter), 
followed by DW images (EPI-DTI, TR/TE 1000/19 ms, 12 segments, 7 b-values from 0 - 700 s/mm², 128 
matrix, NEX 6, respiration-triggered). Analysis of ADC values was performed with the software Beaugui 
developed at INSERM. ADC maps were calculated on a pixel-by-pixel basis using ROOT-based data 
analysis software (ROOT, v5.34.01; CERN, Geneva, Switzerland). The ADC was calculated by fitting the 
normalized signal intensity to a classical monoexponential model (cut-off > 150 s/mm2), using a non-linear 
least square approach with a Levenberg-Marquardt algorithm. Tumor ROIs were defined manually on the 
b = 0 images and then copied onto the ADC maps to determine ADCmean. 
 
Immunohistochemistry  
Formalin-fixed tumor tissue was stained and analyzed as described in detail in the Supplemental Methods.  
 
Thymidine analysis 







Results are expressed as boxplots showing the median and the 25%ile and 75%ile. Error bars depict the 
maximum and minimum values. Mean and standard deviation were plotted for correlation analyses. 
Significances were calculated with the software SigmaPlot 13. Since not all data were normally distributed, 
we used the Mann-Whitney rank sum test to compare groups. Correlations were determined with the 




Molecular imaging of treatment response in Colo205 xenografts 
We established a FOLFOX treatment regime that closely resembles the therapy schedule employed in the 
clinical situation. When given at weekly intervals, the therapy resulted in growth inhibition of Colo205 
xenografts (Fig. 1A, Supplemental Table 2), implying that these tumors are sensitive to FOLFOX.  
[18F]FLT PET imaging revealed a remarkable increase of tracer uptake in FOLFOX treated Colo205 
xenografts at all time points investigated (Figs. 1B and C, Supplemental Table 3). The largest increase 
was observed one day after therapy (9.2-fold relative to baseline, 10.1-fold relative to control). At the end 
of a treatment cycle (d6 and d13) tracer uptake approached baseline levels, but was still significantly 
enhanced. A potential cause of increased [18F]FLT could be the TS inhibitory activity of 5-FU. Therefore, 
we analyzed [18F]FLT uptake in tumors treated with 5-FU on the first day of therapy, when the strongest 
induction of [18F]FLT accumulation could be observed after combination therapy. 5-FU caused a remarkable 
increase in [18F]FLT uptake (SUVmax: control: 1.6 ± 0.4, 5-FU: 11.6 ± 2.5, P < 0.01, 7.1-fold relative to 
control, Fig. 1C). However, the FOLFOX combination resulted in an even stronger increase (SUVmax: 16.5 
± 2.0, P < 0.01 relative to 5-FU), indicating that 5-FU alone is not responsible for the total extent of [18F]FLT 
uptake after FOLFOX therapy. 
We also performed longitudinal DW-MRI studies on FOLFOX treated tumors (Fig. 1D, Supplemental 
Table 4). The resulting ADC maps show a variable and heterogeneous distribution of water diffusion 
(Supplemental Fig. 1). Tumors tended to have lower ADC values over time, irrespective of treatment. 
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Relative to baseline, the ADCmean of FOLFOX treated tumors was significantly decreased on d2, d6, d9 and 
d13 and the ADCmean of control treated tumors was significantly decreased on d9. Tumors of FOLFOX 
treated mice tended to have higher ADC values compared to tumors of control treated animals, an effect 
that was significant on d9. 5-FU treatment alone did not result in changes of water diffusion on day one. 
 
Ex vivo analyses of FOLFOX treated Colo205 xenografts 
Immunohistochemistry showed an increase of Ki67 and TK1 staining in the FOLFOX treated tumors (Fig. 2, 
Supplemental Table 5), implying an increase of cellular proliferation. Elevated TK1 staining was also noted 
on day 1 when mice were treated with 5-FU alone. No statistically significant association of [18F]FLT with 
Ki67 immunohistochemistry could be detected. However, a correlation with TK1 (ρ = 0.893, P < 0.001) was 
observed. 
Western blot analysis confirmed an increase in TK1 expression after FOLFOX therapy and also indicated 
upregulation of the other thymidine metabolism proteins TS and TP (Supplemental Fig. 2 and 
Supplemental Table 6). This prompted us to analyze the levels of thymidine within tumors and in the 
plasma, which were both decreased at later time points in FOLFOX treated animals (Fig. 3 and 
Supplemental Table 7). 
Immunohistochemical analysis of cleaved caspase-3 and a TUNEL assay revealed an increased level of 
cell death only after the second treatment (d9 and d13, Fig. 4, Supplemental Table 8). Other histological 
markers of cell death were not altered (Supplemental Fig. 3). 
Many therapeutic agents induce double-strand breaks in DNA, which result in activation of cellular DNA 
damage response (DDR) mechanisms. A key step of DDR is phosphorylation of the histone variant H2AX, 
producing γH2AX, which is required for assembly of DNA repair proteins (18). Analysis of γH2AX revealed 
prolonged activation of DDR post FOLFOX treatment in Colo205 xenografts, and also one day after 5-FU 
treatment (Fig. 5, Supplemental Table 9). [18F]FLT uptake was correlated with γH2AX staining (ρ = 0.964, 




[18F]FLT PET imaging of non-responsive HCT116 
HCT116 xenografts appear to be non-responsive to FOLFOX, as their growth was not impaired even after 
three cycles of therapy (Fig. 6A, Supplemental Table 10). We analyzed changes of [18F]FLT on day one 
after therapy, as [18F]FLT increase was most pronounced at this time point. No alteration of [18F]FLT was 
observed in HCT116 tumors (Fig. 6B, Supplemental Table 11). 
 
DISCUSSION 
Longitudinal molecular imaging in conjunction with ex vivo molecular analyses were performed to 
investigate alterations induced by a FOLFOX-like combination therapy in CRC models in a clinically 
translatable approach. FOLFOX induced a substantial increase in [18F]FLT uptake, corresponding to 
sustained increases in DDR and proliferation markers. In contrast, [18F]FLT was unaltered in non-
responding HCT116 xenografts implying that the observed increase is predictive for therapy response. 
Prolonged activation of DDR is most likely responsible for the absence of any major changes in tumor cell 
death, which are reflected by unaltered water diffusivity, as assessed by DW-MRI. We speculate that the 
observed alterations are based on this tumor possessing a DNA repair-proficient metabolic phenotype, with 
delayed onset of cell death involving enhanced requirements for nucleosides via the salvage pathway. 
Since [18F]FLT PET is thought to report tumor proliferation and DW-MRI is sensitive to the increase in ADC 
as a consequent of cell death, the two methods are complementary, particularly for monitoring the response 
of tumors to chemotherapy. This allows a comprehensive assessment of the biological processes engaged, 
potentially improving care of cancer patients, especially when the two imaging modalities are conducted in 
combination. 
 
Increase in [18F]FLT uptake in FOLFOX treated xenografts was remarkable. As growth was arrested in the 
treated tumors, one would expect a decrease in uptake of this proliferation tracer rather than an increase. 
In addition, we observed a significant increase in Ki67 immunohistochemical staining. This increased Ki67 
staining is in contradiction to the normal expectation of reduced proliferation in tumors that arrest in growth. 
However, it is in line with a clinical study that observed increased Ki67 expression in CRC liver metastases 
after FOLFOX therapy. The authors concluded that this increase could have resulted from increased 
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proliferation and migration induced by an autocrine mechanism which might be used by metastatic cells 
escaping FOLFOX-induced cell death (19). Possibly in our tumor model the Ki67 signal arose from 
proliferative tumor cells that increased in number relative to non-proliferating tumor cells. Tumor volume 
measurements show that even though in the third treatment week tumor volumes were still significantly 
reduced relative to controls, the tumors tended to grow again. This could possibly imply that there are 
indeed proliferative tumor cells present in the FOLFOX-treated xenografts.  
Western blot analysis implied that TP, TS and TK1 were also upregulated, even though they are involved 
in opposing thymidine pathways. These results were not statistically significant using non-parametric tests, 
likely due to the low sample number. However, it is likely that they are of biological relevance. TS might be 
upregulated as a mechanism of resistance to 5-FU therapy (20), and oxaliplatin has been shown to increase 
expression of TP (21). Increased TK1 expression was in line with respective TK1 immunohistochemistry. It 
has already been reported that inhibition of TS by 5-FU can induce upregulation of TK1, resulting in 
increased accumulation of [18F]FLT (22). In our study, TK1 expression parallels [18F]FLT uptake. At the end 
of a treatment cycle, both approached the levels of controls, implying that tumor biology recedes back to 
baseline levels. This could be caused by the limited plasma half-lives of the therapeutic agents used.  
 
Thymidine within tumors and plasma was decreased on d6, d9 and d13, which could be provoked by the 
catalytic activity of TP (10). Furthermore, TS-inhibitory agents like 5-FU can induce the thymidine salvage 
pathway, resulting in enhanced utilization of thymidine (23). In our model, diminished levels of thymidine 
might also contribute to the increased uptake of [18F]FLT in tumors, as thymidine and [18F]FLT compete for 
cellular uptake and retention (11). 
 
Most of the observed changes (upregulation of thymidine pathway enzymes and [18F]FLT) can probably be 
attributed to the action of 5-FU. However, we demonstrated that equivalent doses of 5-FU alone lead to a 
less pronounced increase in [18F]FLT than the increase provoked by FOLFOX, suggesting that in our 
therapy model TS inhibition is amplified relative to that caused by 5-FU alone. Leucovorin stabilizes the 
complex of 5-FU with TS. Furthermore, it is likely that oxaliplatin-induced increase of TP expression results 
in improved activity of 5-FU, as TP converts 5-FU to one of its active metabolites, 5-fluoro-2’-deoxyuridine 
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(14). It will be interesting to investigate in future experiments, whether the differences in TS inhibition and 
[18F]FLT uptake are related to differences in tumor growth inhibition. 
 
The increase in [18F]FLT uptake in the FOLFOX-responsive Colo205 model appears to be predictive for 
therapy response, as [18F]FLT was unchanged in the non-responsive HCT116 xenografts. Consequently, 
an increase in [18F]FLT accumulation is possibly a prognostic marker for this treatment approach. This 
hypothesis is strengthened by a clinical feasibility study by Kenny et al., measuring [18F]FLT uptake one 
hour after treatment with the 5-FU prodrug capecitabine, showing that tracer uptake parameters did not 
change in breast cancer patients who progressed on therapy, whereas they were increased in responders 
(24). In contrast, Hong et al. observed an increase in [18F]FLT uptake on d2 after FOLFOX treatment 
initiation in CRC patients, which was more pronounced in non-responders than in responders (25). Some 
clinical and preclinical studies have shown that non-therapeutic doses of TS-inhibitory agents can also 
cause an increase in [18F]FLT (26–28), indicating that this change is not predictive of tumor response to 
TS-inhibiting agents. Thus, further investigations are needed, to assess the role of [18F]FLT in the prediction 
of tumor therapy response when employing agents inhibiting TS. 
 
In Colo205 xenografts, we also performed PET imaging with the clinically established metabolism tracer 
[18F]FDG (Supplemental Fig. 4, Supplemental Table 12). [18F]FDG uptake was not consistently altered, 
therewith not reflecting FOLFOX effects. Moreover, [18F]FDG accumulates in inflammatory lesions, so the 
unchanged [18F]FDG also implies that the increase in [18F]FLT observed in this study was not caused by 
inflammatory cells. 
 
In our study, tumor cell death was only slightly increased within the second FOLFOX treatment cycle, as 
measured by caspase-3 IHC and TUNEL. In contrast, other histological markers of cell death (cellular 
density, necrotic area) were unaltered. These results provide a plausible explanation for why we did not 
detect a FOLFOX-induced increase of ADCmean. The observed differences in water diffusion occurred at all 
time points investigated, and do not appear to be of physiological relevance.  
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Histological analysis revealed sustained activation of the DDR marker H2AX after FOLFOX or 5-FU 
therapy, which could be caused by oxaliplatin or 5-FU (29,30). 5-FU induced DDR has been described to 
occur in S-phase (31). Hence, it is likely that also the DDR observed here is linked to this phase, which is 
in line with sustained TK1 expression, which is S-phase specific. In our study, elevated γH2AX was 
observed at all time points, even though levels approached those of control levels at the end of the first 
treatment cycle (d6). Decreasing γH2AX expression might suggest either successful repair of the DNA 
damage, or lysis of dead cells (32). As no induction of cell death was observed on d6 after FOLFOX and 
immunohistochemical markers of proliferation were increased, it is likely that the DNA damage was 
successfully repaired. Hence, attempts of the tumor cell to repair DNA double-strand breaks might delay 
induction of cell death, explaining unchanged ADCmean.  
Increased amounts of nucleosides are needed during DDR. Consequently, DDR in the treated tumors could 
potentially contribute to the increased [18F]FLT uptake observed here. γH2AX expression parallels [18F]FLT 
uptake and we detected a correlation of [18F]FLT uptake and γH2AX expression, supporting our hypothesis 
of increased nucleoside consumption during DDR.  
 
A limitation of this study is that we did not evaluate tumors treated with single agents, apart from the analysis 
of a single time point for 5-FU. Such an analysis would help to assess the relative contribution of each agent 
to the observed changes. However, single agents are rarely employed in the clinical setting. Therefore, our 
data shed light on changes induced by a clinically relevant therapy approach. It would be of interest to 
assess FOLFOX induced mechanisms in a broader panel of tumor types including non-responsive models 
and clinical tumor specimens.  
 
CONCLUSION 
Factors resulting in an increase of [18F]FLT uptake can be manifold, including increased cellular proliferation 
(Ki67), DNA-salvage-pathway utilization (TK1), and DDR activity, as well as thymidine levels. These 
parameters might be modulated by tumor treatment, as demonstrated here for a FOLFOX combination 
therapy as well as a 5-FU monotherapy. Consequently, in this scenario, changes in [18F]FLT reflect 
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alterations in these pathways, which are not directly related to tumor therapy response, as in general a 
reduced proliferation (and [18F]FLT accumulation) is associated with tumor therapy response.  
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FIGURE 1. In Colo205 xenografts, FOLFOX therapy resulted in tumor growth arrest, increase in [18F]FLT 
uptake and no increase in ADCmean. (A) Caliper measurements revealed a growth inhibitory effect of 




































































































































representative FOLFOX treated mouse show that tumor [18F]FLT uptake was remarkably enhanced after 
therapy. Imaging on d6 was not performed on the mouse presented here. The images also show the fiducial 
markers used for co-registration with MR images. Arrows point to the two tumors. (C) Quantification of 
tumor [18F]FLT uptake revealed a remarkable increase of SUVmax relative to baseline after FOLFOX. (D) 
Significant reductions in ADCmean relative to baseline could be observed during the growth of FOLFOX and 
control treated tumors. White: control, grey: FOLFOX, striped: 5-FU; *: P < 0.05, **: P < 0.01, ***: P < 0.001 
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FIGURE 2. In Colo205 bearing mice, FOLFOX therapy resulted in an increase of histological proliferation 
markers. (A) Heatmaps depicting the density of Ki67-positive nuclei of representative tumors are shown in 
the upper panel. The percentage positive nuclei was quantified and related to [18F]FLT uptake. (B) TK1 
staining was quantified as positively stained area. Scale bar = 100 µm. White: control, grey: FOLFOX, 
striped: 5-FU; *: P < 0.05, ***: P < 0.001 relative to control. 
 
FIGURE 3. Thymidine levels were decreased in FOLFOX treated Colo205 tumors, as measured by  liquid-
chromatography-tandem mass spectrometry . White: control, grey: FOLFOX, striped: 5-FU; *: P < 0.05, **: 
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FIUGRE 4. Immunohistochemistry of activated caspase-3 and TUNEL assay of Colo205 tumors implied an 
increase in cell death after the second FOLFOX treatment. Scale bar = 100 µm. White: control, grey: 
FOLFOX, striped: 5-FU; *: P < 0.05, **: P < 0.01 relative to control. 
control d1 d2
FOLFOX






















































control d1 d2 d6 d9 d13 d1
5-FU FOLFOX




FIGURE 5. DDR is activated after FOLFOX therapy as determined by immunohistochemistry of γH2AX. 
The positively stained area was quantified and related to [18F]FLT uptake. Scale bar = 100 µm. White: 
control, grey: FOLFOX, striped: 5-FU; *: P < 0.05, **: P < 0.01 relative to control. 
 
 
FIGURE 6. FOLFOX therapy in HCT116 xenografts affects neither tumor growth nor [18F]FLT uptake. (A) 
Tumor volumes were determined by caliper measurements. Therapy was applied in weekly intervals. (B) 
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